DSpace Repositorium (Manakin basiert)

A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study

Zur Kurzanzeige

dc.contributor.author Giovannoni, Gavin
dc.contributor.author Boyko, Alexey
dc.contributor.author Correale, Jorge
dc.contributor.author Edan, Gilles
dc.contributor.author Freedman, Mark S.
dc.contributor.author Montalban, Xavier
dc.contributor.author Rammohan, Kottil
dc.contributor.author Stefoski, Dusan
dc.contributor.author Yamout, Bassem
dc.contributor.author Leist, Thomas
dc.contributor.author Aydemir, Aida
dc.contributor.author Borsi, Laszlo
dc.contributor.author Verdun di Cantogno, Elisabetta
dc.date.accessioned 2024-02-23T14:28:12Z
dc.date.available 2024-02-23T14:28:12Z
dc.date.issued 2023-08-03
dc.identifier.citation Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, di Cantogno EV. A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study. Neurodegener Dis Manag. 2023 Oct;13(5):261-268. doi: 10.2217/nmt-2023-0018 es_ES
dc.identifier.uri https://doi.org/10.2217/nmt-2023-0018
dc.identifier.uri https://repositorio.fleni.org.ar/xmlui/handle/123456789/1011
dc.description.abstract What is this summary about?: Previous studies have shown that people living with multiple sclerosis (MS) treated with cladribine tablets have fewer relapses (where new symptoms occur or existing symptoms get worse for 24 hours or more) and delayed disability progression (slowing down of the disease getting worse). The CLASSIC-MS study looked at the long-term effectiveness of treatment with cladribine tablets in people living with MS who had taken part in the original CLARITY and CLARITY Extension clinical studies. What were the results?: Results showed that people treated with cladribine tablets maintained their mobility (the ability to move freely) for longer and experienced other positive effects long after their treatment ended, including being less likely to need further treatment for their MS. What do the results mean?: The results obtained from CLASSIC-MS show that the benefits of taking cladribine tablets carry on even when patients stop taking the treatment. es_ES
dc.language.iso eng es_ES
dc.publisher Future Medicine es_ES
dc.rights info:eu-repo/semantics/openAccess
dc.subject Cladribine es_ES
dc.subject Cladribina es_ES
dc.subject Immunosuppressive Agents es_ES
dc.subject Inmunosupresores es_ES
dc.subject Multiple Sclerosis, Relapsing-Remitting es_ES
dc.subject Esclerosis Múltiple Recurrente-Remitente es_ES
dc.subject Recurrence es_ES
dc.subject Recurrencia es_ES
dc.title A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study es_ES
dc.type info:eu-repo/semantics/article es_ES
dc.type info:eu-repo/semantics/publishedVersion
dc.description.fil Fil: Correale, Jorge. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina.
dc.relation.ispartofVOLUME 13
dc.relation.ispartofNUMBER 5
dc.relation.ispartofPAGINATION 261-268
dc.relation.ispartofCOUNTRY Reino Unido
dc.relation.ispartofCITY Londres
dc.relation.ispartofTITLE Neurodegenerative disease management
dc.relation.ispartofISSN 1758-2032
dc.type.snrd info:ar-repo/semantics/artículo es_ES


Dateien zu dieser Ressource

Das Dokument erscheint in:

Zur Kurzanzeige

DSpace Suche


Stöbern

Mein Benutzerkonto

Statistik